PRNewsWire
22 Jul 2026, 11:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Ukraine's Ministry of Health has accepted Valion Bio's Entolimod regulatory dossier for formal review under the Regulatory Equivalence Pathway. — This is the first allied-nation regulatory review of the drug, validating the product's potential and opening a new path to international commercialization.
+0.60The technical review for Entolimod in Ukraine could be completed in as little as 45 to 60 days. — A rapid regulatory timeline accelerates the potential for official approval and subsequent government procurement contracts.
+0.40Valion Bio has demonstrated a 200-fold manufacturing scale-up via Velocity Bioworks, capable of producing approximately 1.3 million human doses. — Proving the ability to scale production removes a major execution risk for fulfilling large national-stockpile orders.
+0.30Which stocks this story touches
Continue reading
6 related stories
Search tags
The company reached a significant milestone as Ukraine's Ministry of Health accepted its Entolimod dossier for formal regulatory review.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Proactive Investors
7h ago
